\
&
Contact us
This was 3 years ago
LocationBrussels
ProgrammesThis September, a delegation from Spain of about 40 companies/organisations from the Spanish regions Extremadura, La Rioja, Navarra and Aragón, will visit Brussels. They are interested in meeting companies, research organisations, universities, ... from Flanders in the framework of Horizon Europe call topics. The B2B meeting with stakeholders from Flanders is organised by Enterprise Europe Network (E.E.N.) Flanders, supported by NCP Flanders, Flanders Innovation and Entrepreneurship (VLAIO) and Flanders Investment and Trade (FIT).
Spanish participants have provided their profiles and preference for Horizon Europe topics, as well as the description of the Belgian partners sought for B2B meetings to build consortiums for joint Horizon Europe proposals - all in the form of a catalogue. You can consult the finalised catalogue of interested companies here.
You can express your interest in a specific Spanish company's/organisation's profile by email: mail to greet.devos@vlaio.be, patrick.demolder@vlaio.be and arnout.geys@fitagency.be if you are interested to join this matchmaking event.
Further practical information of this event will be made available early September.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.